Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shujinkechuan is a medicinal product developed by Guangzhou Jifeng Industrial Co., Ltd., primarily indicated for the treatment of bronchial asthma and associated respiratory conditions. It is formulated as a Traditional Chinese Medicine (TCM) or herbal remedy designed to alleviate cough, facilitate the expulsion of phlegm, and relieve bronchospasm. The product's name implies a dual therapeutic focus on relaxing musculoskeletal tension ('Shujin') and addressing cough and asthma ('Kechuan'), reflecting its use in broader traditional contexts for both respiratory and rheumatic symptoms. Typically administered orally in capsule form, Shujinkechuan is marketed for its purported bronchodilatory and anti-inflammatory effects. However, it has been the subject of regulatory scrutiny in several jurisdictions, including alerts regarding the potential presence of undeclared synthetic pharmaceutical ingredients in some batches.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shujinkechuan.